A 5-year enhanced Pharmacovigilance surveillance initiative to survey and characterise spontaneous occurrence and experience of ketoacidotic events in patients treated with Empagliflozin –containing products First published 20/06/2018 Last updated 02/04/2024 EU PAS number:EUPAS21696 Study Ongoing